Vivimed Labs: Annual Secretarial Compliance Report for FY26
Vivimed Labs Limited filed its Annual Secretarial Compliance Report for the financial year ending 31 March 2026. The report, issued by Practicing Company Secretary N.V.S.S. Suryanarayana Rao on 30 April 2026, confirms compliance with SEBI regulations and good corporate practices.
The announcement is a standard compliance report and is unlikely to have a significant impact on the company's stock price or operations.
The announcement is a routine compliance filing and does not contain any information that would indicate a positive or negative sentiment.
Vivimed Labs Limited has submitted the Annual Secretarial Compliance Report for the financial year ended 31 March 2026, as per Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report, dated 30 April 2026, was issued by Mr. N.V.S.S. Suryanarayana Rao, a Practicing Company Secretary. The report confirms compliance with statutory provisions and adherence to good corporate practices.
The Secretarial Review, conducted by N.V.S.S. Suryanarayana Rao, involved examining various documents, records, and information provided by Vivimed Labs and its representatives. The review ensured compliance with the SEBI Act, Securities Contracts (Regulation) Act, and regulations pertaining to listing obligations, disclosure requirements, substantial acquisition of shares, insider trading, and depositories.
The report also confirms the company's adherence to Secretarial Standards issued by the ICSI, timely updation of policies, maintenance of a functional website, and proper preservation of documents. It further states that none of the company's directors are disqualified under Section 164 of the Companies Act, 2013, and that the company has obtained prior approval of the Audit Committee for all related party transactions.
What to do with a filing like this
Vivimed Labs Limited filed this with the NSE as a statutory disclosure, categorised under secretarial compliance report. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Vivimed Labs Limited. Read the original for the full detail.